| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
We hypothesized that NEC contains a subpopulation of cancer stem cells (CSCs), we examined expression and role of lumican and CSC marker in gastrointestinal neuroendocrine carcinoma (NEC). Cytoplasm and tumor stroma were positively stained for lumican by immunohistochemcal analysis. We used established cell line (NENMS-1) derived from ascending colon NEC cancer patient. Src，CD133 and lumican mRNA were over expressed in sphere than wild by quantitative RT-PCR analyses. Lumican-overexpressing NENMS-1 was reduced cell growth, sphere formation and cell migration compared with wild and Control-GFP. CD133 and lumican mRNA expression were high in positive compartmentation by aldefluor assay. From the above, it was suggested lumican may become a CSC marker for gastrointestinal NEC.
|
